Results 101 to 110 of about 69,283 (286)
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Abstract There is increasing concern regarding pollutants disrupting the vertebrate thyroid hormone (TH) system, which is crucial for development. Thus, identification of TH system–disrupting chemicals (THSDCs) is an important requirement in the Organisation for Economic Co‐operation and Development (OECD) testing framework.
Lisa Gölz +9 more
wiley +1 more source
Targeting protein–protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease [PDF]
The cAMP signaling system can trigger precise physiological cellular responses that depend on the fidelity of many protein–protein interactions, which act to bring together signaling intermediates at defined locations within cells.
Brunton +8 more
core +1 more source
Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
To identify the criteria of phosphodiesterase type 5 inhibitor (PDE5i) users and to analyse the knowledge, attitude, and practices of PDE5i use amongst Saudi men.A web-based, cross-sectional survey was conducted in Saudi Arabia between January and April 2015.
Alshahrani, Saad +5 more
openaire +2 more sources
Abstract Background Racehorses undergo profound physiological changes with training and competition, but current biomarkers inadequately capture the complex molecular dynamics of exercise. This study aimed to identify novel plasma biomarkers of training adaptation and peak load using high‐throughput proteomics.
Jowita Grzędzicka +4 more
wiley +1 more source
AB030. Evolution of phosphodiesterase type 5 inhibitors [PDF]
After launching of sildenafil citrate, the last invention of 20(th) century, in 1998, oral phosphodiesterase type 5 (PDE5) inhibitor has been established as first line treatment of erectile dysfunction and shift new paradigm of diagnosis and treatment of erectile dysfunction.
europepmc +3 more sources
The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference! [PDF]
Kinetoplastids are unicellular, eukaryotic, flagellated protozoans containing the eponymous kinetoplast. Within this order, the family of trypanosomatids are responsible for some of the most serious human diseases, including Chagas disease (Trypanosoma ...
De Koning, Harry P. +2 more
core +1 more source
In this review, agents such baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone, as well as minocycline have been implicated as neuroprotective agents for irradiation‐induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin,
Seidu A. Richard +2 more
wiley +1 more source
Avanafil for treatment of erectile dysfunction: review of its potential
Ryan M Burke,1 Jeffery D Evans21The University of Louisiana at Monroe College of Pharmacy, Monroe, LA, 2The University of Louisiana at Monroe College of Pharmacy, Shreveport, LA, USAAbstract: Avanafil is a medication that was recently approved by the US ...
Burke RM, Evans JD
doaj
The role of endothelin-1 in pulmonary arterial hypertension. [PDF]
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core +1 more source

